Gongwin Biopharm Holdings Co., Ltd.

6617

KYG409471060

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 03:30:00 09/05/2024 am IST			5-day change	1st Jan Change
190.5 ^TWD	-0.26%		+5.25%	+3.25%

08/05	Gongwin Biopharm Co., Ltd. announced that it expects to receive TWD 300 million in funding from Gongwin Biopharm Holdings Co., Ltd.	CI
12/04	Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Gongwin Biopharm Holdings Co., Ltd.(GTSM:6617) added to S&P Global BMI Index

September 21, 2020 at 09:30 am IST

Latest news about Gongwin Biopharm Holdings Co., Ltd.

Gongwin Biopharm Co., Ltd. announced that it expects to receive TWD 300 million in funding from Gongwin Biopharm Holdings Co., Ltd.	08/05	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	12/04	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	28/11	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	14/23/14	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	24/23/24	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	10/22/10	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	14/22/14	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	13/21/13	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	11/21/11	CI
Gongwin Biopharm Holdings Co., Ltd.(GTSM:6617) added to S&P Global BMI Index	21/20/21	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	12/20/12	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	13/19/13	CI
Gongwin Biopharm Holdings Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	18/19/18	CI

Chart Gongwin Biopharm Holdings Co., Ltd.

Duration

Period

Chart Gongwin Biopharm Holdings Co., Ltd.

More charts

Gongwin Biopharm Holdings Co Ltd is a company engaged in the research and development of anti-cancer medicine, especially focuses on the precise treatment to tumors. The Companyâs headquarter is located in Taiwan and it created a cross-regional platform composed of Taiwan, China Mainland and the United States. The new PTS drug researched and developed by the Company is a new drug product for cancer treatment combined with minimally invasive interventional therapy technology, including PTS100 for the treatment of liver cancer, PTS302 for the treatment of lung cancer, PTS-02 for the treatment of rare diseases, PTS500 for the treatment of malignant pleural effusion and pets medication GWA101 and others.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
GONGWIN BIOPHARM HOLDINGS CO., LTD.	+3.25%	666M
VERTEX PHARMACEUTICALS INCORPORATED	+2.97%	108B
REGENERON PHARMACEUTICALS, INC.	+10.21%	104B
ARGENX SE	+2.53%	22.33B
BIONTECH SE	-12.77%	22.19B
GENMAB A/S	-7.05%	18.69B
WUXI APPTEC CO., LTD.	-37.64%	17.74B
BEIGENE, LTD.	-6.50%	17.64B
NEUROCRINE BIOSCIENCES, INC.	+6.00%	14.05B
SAREPTA THERAPEUTICS, INC.	+37.20%	12.51B

Bio Therapeutic Drugs